It’s just the start of 2019 but we’re already thinking about fall and the federal election it brings with it. Last year, there was a lot of talk about the establishment of a national pharmacare plan. The federal government assembled a working group to study the best way a system like this would work in Canada.

February is here, which means Valentine’s Day is around the corner. Valentine’s is a day that you either love or hate. And throwing the C-word into the mix can make it hard even when it’s something you’re usually excited for.

Last month, we had the opportunity to attend the 2018 San Antonio Breast Cancer Symposium (SABCS). Here’s some of the key highlights to come out of the conference. 

Last month, we connected with Alan from ODANO, the Oncology Drug Access Navigators of Ontario, to answer a few questions about who they are and how they help patients in Ontario access life-saving medications.

That’s what Dr. Majumder and her team of researchers at Brandon University in Manitoba are hoping to find out. Dr. Majumder, Assistant Professor in Cancer Genetics and Cell Biology, is screening blood plasma from breast cancer patients and patients who don’t have breast cancer to determine if there is a blood biomarker like micro RNA (miRNA) that could potentially tell us when breast cancer is present or growing in a person.

Inflammatory breast cancer (IBC) is a rare and aggressive form of the disease that doesn’t get a lot of attention. It’s tough to diagnose because of its unusual symptoms, and it’s more common in young women which makes it particularly tricky since the symptoms mimic that of mastitis, a common breast infection in new moms who breastfeed. Here’s what you need to know:

People have known about breast cancer since ancient times.  For most of that time, there were no effective treatments.  However, in the last 120 years, advances in surgical and medical treatments have meant that today, 98 percent of patients with localized breast cancer survive at least five years after diagnosis.  The following timeline shows the development of breast cancer treatments.

Biosimilar drug development involves many of the same steps that a biologic drug goes through but with a different focus. 

Meditation programs are popping up across Canada – and for good reason.   This centuries-old practice, also known as mindfulness, is one of the best tools for our health, well-being, and happiness.  Research shows a daily meditation practice reduces stress, depression, and inflammation while improving sleep, fatigue, and menopausal symptoms in women who have a breast cancer diagnosis.   Additionally, studies connect meditation and an enhanced immune function.  These are all important considerations when you’ve had a breast cancer diagnosis.

Biosimilar therapies have already been in use in Canada for a few years, mostly in the chronic disease and supportive care settings. But soon they will be used for treating cancer as well. There isn’t a lot of information about these new oncology biosimilars and it’s important that breast cancer patients are aware of how their treatment plans may be impacted by these new therapies. We explore some of the emerging biosimilar therapies that will be used to treat cancer patients soon.